You are here

  • Home
  • Archive
  • Volume 94, Issue 6
  • Has the introduction of HIV pre-exposure prophylaxis had an impact on HIV post-exposure prophylaxis for sexual exposure prescriptions in men who have sex with men in the UK’s largest health board?

Article Text

Article menu
Download PDFPDF
Letter
Has the introduction of HIV pre-exposure prophylaxis had an impact on HIV post-exposure prophylaxis for sexual exposure prescriptions in men who have sex with men in the UK’s largest health board?
  1. Laura Gillespie1,
  2. Monica Lowrie2,
  3. Rebecca Metcalfe1
  1. 1 Sandyford Sexual Health Service, Glasgow, UK
  2. 2 School of Medicine, University of Glasgow, Glasgow, UK
  1. Correspondence to Dr Laura Gillespie, Sandyford Sexual Health Service, Glasgow, G3 7NB, UK; lgillespie1{at}nhs.net

https://doi.org/10.1136/sextrans-2018-053734

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Background

    In April 2017, the Scottish Medicine Consortium approved emtricitabine/tenofovir disoproxil for use as HIV pre-exposure prophylaxis (PrEP), in combination with safer sex practices.1 National Health Service (NHS) Greater Glasgow and Clyde (GG&C) provides healthcare to >1.2 million people, with a prevalence of HIV in men who have sex with men (MSM) of 5.4%.2 HIV post-exposure prophylaxis for sexual exposure (PEPSE) is available at Sexual Health services …

    View Full Text

    Footnotes

    • Contributors Data collection by LG, ML and RM. Letter edited by LG and RM.

    • Competing interests None declared.

    • Provenance and peer review Not commissioned; internally peer reviewed.